Treatment of small cell lung cancer
Publikation: Bidrag til bog/antologi/rapport › Bidrag til bog/antologi › Forskning › fagfællebedømt
Standard
Treatment of small cell lung cancer. / Langer, Seppo W.; Sørensen, Morten.
Lung Cancer Therapy Annual. CRC Press, 2008. s. 91-114.Publikation: Bidrag til bog/antologi/rapport › Bidrag til bog/antologi › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - CHAP
T1 - Treatment of small cell lung cancer
AU - Langer, Seppo W.
AU - Sørensen, Morten
PY - 2008/1/1
Y1 - 2008/1/1
N2 - During the past three decades, treatment progress in small cell lung cancer (SCLC) has been modest and mainly achieved in patients staged as having limited disease (LD-SCLC) by the addition and refining of locoregional radiation to systemic chemotherapy. Three landmarks have been accomplished: (1) the addition of thoracic radiation therapy to systemic chemotherapy; (2) the demonstration of the superiority of early and/or twice-daily radiation therapy compared with late, once-daily fractionation; and (3) prophylactic radiation therapy of the brain, the so-called prophylactic cranial irradiation (PCI). Each of these innovations has contributed to an improvement of the 5-year survival rate in LD-SCLC. In contrast, progress in the treatment of patients with extensive disease (ED-SCLC) has been very modest. However, recently a significant step towards further improvement of palliative treatment has emerged with the demonstration that PCI also plays a definite role in the treatment of extensive disease.1
AB - During the past three decades, treatment progress in small cell lung cancer (SCLC) has been modest and mainly achieved in patients staged as having limited disease (LD-SCLC) by the addition and refining of locoregional radiation to systemic chemotherapy. Three landmarks have been accomplished: (1) the addition of thoracic radiation therapy to systemic chemotherapy; (2) the demonstration of the superiority of early and/or twice-daily radiation therapy compared with late, once-daily fractionation; and (3) prophylactic radiation therapy of the brain, the so-called prophylactic cranial irradiation (PCI). Each of these innovations has contributed to an improvement of the 5-year survival rate in LD-SCLC. In contrast, progress in the treatment of patients with extensive disease (ED-SCLC) has been very modest. However, recently a significant step towards further improvement of palliative treatment has emerged with the demonstration that PCI also plays a definite role in the treatment of extensive disease.1
UR - http://www.scopus.com/inward/record.url?scp=85057669257&partnerID=8YFLogxK
M3 - Book chapter
AN - SCOPUS:85057669257
SN - 9780415465458
SP - 91
EP - 114
BT - Lung Cancer Therapy Annual
PB - CRC Press
ER -
ID: 248230845